Skip to main content
SpringerLink
Log in
Book cover

Side Effects of Medical Cancer Therapy pp 179–212Cite as

Side Effects of Medical Cancer Therapy in Genitourinary Malignancies

  • Chapter
  • First Online:

  • 1000 Accesses

Abstract

Genitourinary cancers represent 12.8% of cancer in both sexes and 21.5% in men, accounting for 7% of cancer deaths in both sexes and 10.5% in men. The systemic treatment of prostate cancer and renal cell carcinoma does not rely on chemotherapy, with the exception of taxane docetaxel and cabazitaxel. Prostate cancer is primarily treated by androgen deprivation, by surgical castration or LHRH analogs, or by androgen receptor pathway inhibitor enzalutamide and abiraterone acetate. Renal cell carcinoma is nowadays treated with agents targeting survival and angiogenesis pathways, including tyrosine kinase inhibitors (TKIs) sorafenib, sunitinib, axitinib, and pazopanib; anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab; mammalian target of rapamycin (mTOR) inhibitors temsirolimus and everolimus; and oral inhibitor of tyrosine kinases MET, VEGFR, AXL, cabozantinib. Most recently, immune checkpoint inhibitors have made their way to genitourinary cancers, revolutionizing the treatment of urothelial cancers and renal cell carcinoma.

Hormone therapies and targeted therapies don’t eradicate prostate cancer and renal cell carcinoma but rather switch them to a more chronic state. This means that these treatments are prescribed chronically for an extended period of time. In such conditions, even the least bothersome side effect may profoundly alter the quality of life of patients. Ultimately, this is a threat to compliance and then to the efficacy of these treatments. In addition, many of the side effects of these drugs often overlap with common chronic illnesses such as diabetes, hypertension, hypercholesterolemia, heart failure, and osteoporosis. An exhaustive knowledge of these side effects, proper monitoring, and in-depth education of patients are key elements to secure the efficacy of these treatments.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Ferlay J et al.. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase, Lyon. International Agency for Research on Cancer; 2013. http://globocan.iarc.fr/. Accessed 1 July 2017.

  2. Wolff RF, et al. A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer. Eur J Cancer. 2015;51:2345–67. https://doi.org/10.1016/j.ejca.2015.07.019.

    Article  PubMed  Google Scholar 

  3. Gillessen S, et al. Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol. 2017;17:30497–9. https://doi.org/10.1016/j.eururo.2017.06.002.

    Article  Google Scholar 

  4. Tannock IF, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.

    Article  CAS  PubMed  Google Scholar 

  5. Beer TM, et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017;71:151–4. https://doi.org/10.1016/j.eururo.2016.07.032.

    Article  PubMed  CAS  Google Scholar 

  6. Fizazi K, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–60. https://doi.org/10.1056/NEJMoa1704174.

    Article  PubMed  CAS  Google Scholar 

  7. James ND, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338–51. https://doi.org/10.1056/NEJMoa1702900.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. James ND, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–77. https://doi.org/10.1016/S0140-6736(15)01037-5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Sweeney CJ, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–46. https://doi.org/10.1056/NEJMoa1503747.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Huggins C, Hodges C. Studies on prostate cancer. I. The effect of castration, of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293.

    CAS  Google Scholar 

  11. Cornford P, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630–42. https://doi.org/10.1016/j.eururo.2016.08.002.

    Article  PubMed  Google Scholar 

  12. Gomella LG. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues. BJU Int. 2007;99(Suppl 1):25–9. discussion 30.

    Article  PubMed  Google Scholar 

  13. Holzbeierlein JM. Managing complications of androgen deprivation therapy for prostate cancer. Urol Clin North Am. 2006;33:181–190, vi.

    Article  PubMed  Google Scholar 

  14. Nguyen PL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2014;67(5):825–36. https://doi.org/10.1016/j.eururo.2014.07.010.

    Article  PubMed  CAS  Google Scholar 

  15. Moyad MA. Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients. Urol Oncol. 2005;23:56–64.

    Article  PubMed  Google Scholar 

  16. Mottet N, Prayer-Galetti T, Hammerer P, Kattan MW, Tunn U. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int. 2006;98:20–7.

    Article  PubMed  Google Scholar 

  17. Moyad MA, Merrick GS. Statins and cholesterol lowering after a cancer diagnosis: why not? Urol Oncol. 2005;23:49–55.

    Article  PubMed  Google Scholar 

  18. Barton D, et al. A phase III trial evaluating three doses of citalopram for hot flashes: NCCTG trial N05C9. J Clin Oncol. 2008;26:A9538.

    Article  Google Scholar 

  19. Loprinzi CL, et al. Transdermal clonidine for ameliorating post-orchiectomy hot flashes. J Urol. 1994;151:634–6.

    Article  CAS  PubMed  Google Scholar 

  20. Loprinzi CL, et al. Gabapentin for hot flashes in men: NCCTG trial N00CB. J Clin Oncol. 2007;25:A9005.

    Article  CAS  Google Scholar 

  21. Spetz Holm AC, Frisk J, Hammar ML. Acupuncture as treatment of hot flashes and the possible role of calcitonin gene-related peptide. Evid Based Complement Alternat Med. 2012;2012:579321. https://doi.org/10.1155/2012/579321.

    Article  PubMed  Google Scholar 

  22. Vandecasteele K, Ost P, Oosterlinck W, Fonteyne V, Neve WD, Meerleer GD. Evaluation of the efficacy and safety of salvia Officinalis in controlling hot flashes in prostate cancer patients treated with androgen deprivation. Phytother Res. 2012;26:208–13. https://doi.org/10.1002/ptr.3528.

    Article  PubMed  Google Scholar 

  23. Potosky AL, et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst. 2002;94:430–7.

    Article  PubMed  Google Scholar 

  24. Aucoin MW, Wassersug RJ. The sexuality and social performance of androgen-deprived (castrated) men throughout history: implications for modern day cancer patients. Soc Sci Med. 2006;63:3162–73.

    Article  PubMed  Google Scholar 

  25. Walker LM, Hampton AJ, Wassersug RJ, Thomas BC, Robinson JW. Androgen deprivation therapy and maintenance of intimacy: a randomized controlled pilot study of an educational intervention for patients and their partners. Contemp Clin Trials. 2013;34:227–31. https://doi.org/10.1016/j.cct.2012.11.007.

    Article  PubMed  Google Scholar 

  26. Bourke L, et al. Exercise for men with prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;69:693–703. https://doi.org/10.1016/j.eururo.2015.10.047.

    Article  PubMed  Google Scholar 

  27. Demark-Wahnefried W, et al. Main outcomes of the FRESH START trial: a sequentially tailored, diet and exercise mailed print intervention among breast and prostate cancer survivors. J Clin Oncol. 2007;25:2709–18.

    Article  PubMed  Google Scholar 

  28. Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology. 2003;61:32–8.

    Article  PubMed  Google Scholar 

  29. Fang F, Keating NL, Mucci LA, Adami HO, Stampfer MJ, Valdimarsdottir U, Fall K. Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States. J Natl Cancer Inst. 2010;102:307–14. https://doi.org/10.1093/jnci/djp537.

    Article  PubMed  Google Scholar 

  30. Dinh KT, et al. Association of androgen deprivation therapy with depression in localized prostate cancer. J Clin Oncol. 2016;34:1905–12. https://doi.org/10.1200/JCO.2015.64.1969.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Hinz A, Mehnert A, Kocalevent RD, Brahler E, Forkmann T, Singer S, Schulte T. Assessment of depression severity with the PHQ-9 in cancer patients and in the general population. BMC Psychiatry. 2016;16:22. https://doi.org/10.1186/s12888-016-0728-6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Wu LM, Tanenbaum ML, Dijkers MP, Amidi A, Hall SJ, Penedo FJ, Diefenbach MA. Cognitive and neurobehavioral symptoms in patients with non-metastatic prostate cancer treated with androgen deprivation therapy or observation: a mixed methods study. Soc Sci Med. 2016;156:80–9. https://doi.org/10.1016/j.socscimed.2016.03.016.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Nead KT, Sinha S, Nguyen PL. Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2017;20(3):259–64. https://doi.org/10.1038/pcan.2017.10.

    Article  PubMed  CAS  Google Scholar 

  34. Jhan JH, Yang YH, Chang YH, Guu SJ, Tsai CC. Hormone therapy for prostate cancer increases the risk of Alzheimer’s disease: a nationwide 4-year longitudinal cohort study. Aging Male. 2017;20:33–8. https://doi.org/10.1080/13685538.2016.1271782.

    Article  PubMed  CAS  Google Scholar 

  35. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol. 1997;79:933–41.

    Article  CAS  PubMed  Google Scholar 

  36. Nanda A, Chen MH, Braccioforte MH, Moran BJ, D’Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009;302:866–73. https://doi.org/10.1001/jama.2009.1137.

    Article  PubMed  CAS  Google Scholar 

  37. Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65:565–73. https://doi.org/10.1016/j.eururo.2013.10.032.

    Article  PubMed  CAS  Google Scholar 

  38. Tivesten A, Pinthus JH, Clarke N, Duivenvoorden W, Nilsson J. Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanisms. Urol Oncol. 2015;33:464–75. https://doi.org/10.1016/j.urolonc.2015.05.030.

    Article  PubMed  CAS  Google Scholar 

  39. Scailteux LM, et al. Androgen deprivation therapy and cardiovascular risk: no meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French health insurance data. Eur J Cancer. 2017;77:99–108. https://doi.org/10.1016/j.ejca.2017.03.002.

    Article  PubMed  CAS  Google Scholar 

  40. Galvao DA, et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int. 2008;102:44–7.

    Article  PubMed  Google Scholar 

  41. Galvao DA, Taaffe DR, Spry N, Joseph D, Turner D, Newton RU. Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis. 2008;12:198–203.

    Article  PubMed  Google Scholar 

  42. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24:3979–83.

    Article  PubMed  Google Scholar 

  43. Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, Finkelstein JS. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 2008;112:2188–94.

    Article  CAS  PubMed  Google Scholar 

  44. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91:1305–8.

    Article  CAS  PubMed  Google Scholar 

  45. Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102:39–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68:386–96. https://doi.org/10.1016/j.eururo.2014.11.039.

    Article  PubMed  Google Scholar 

  47. Nguyen PL, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306:2359–66. https://doi.org/10.1001/jama.2011.1745.

    Article  PubMed  CAS  Google Scholar 

  48. Levine GN, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010;121:833–40. https://doi.org/10.1161/CIRCULATIONAHA.109.192695.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Food and Drug Administration. FDA drug safety communication: update to ongoing safety review of GnRH agonists and notification to manufacturers of GnRH agonists to add new safety information to labeling regarding increased risk of diabetes and certain cardiovascular diseases. 2010. http://www.fda.gov/Drugs/DrugSafety/ucm229986.htm.

  50. Schow DA, Renfer LG, Rozanski TA, Thompson IM. Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J. 1998;91:855–7.

    Article  CAS  PubMed  Google Scholar 

  51. Nobes JP, Langley SE, Klopper T, Russell-Jones D, Laing RW. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int. 2011;109(10):1495–502. https://doi.org/10.1111/j.1464-410X.2011.10555.x.

    Article  PubMed  CAS  Google Scholar 

  52. Galvao DA, et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc. 2006;38:2045–52.

    Article  PubMed  Google Scholar 

  53. Segal RJ, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2003;21:1653–9.

    Article  PubMed  Google Scholar 

  54. Segal RJ, et al. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol. 2009;27:344–51.

    Article  PubMed  Google Scholar 

  55. Baumann FT, Zopf EM, Bloch W. Clinical exercise interventions in prostate cancer patients--a systematic review of randomized controlled trials. Support Care Cancer. 2012;20:221–33. https://doi.org/10.1007/s00520-011-1271-0.

    Article  PubMed  Google Scholar 

  56. Eriksson S, Eriksson A, Stege R, Carlstrom K. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int. 1995;57:97–9.

    Article  CAS  PubMed  Google Scholar 

  57. Fink HA, Ewing SK, Ensrud KE, Barrett-Connor E, Taylor BC, Cauley JA, Orwoll ES. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab. 2006;91:3908–15. https://doi.org/10.1210/jc.2006-0173.

    Article  PubMed  CAS  Google Scholar 

  58. Murphy S, Khaw KT, Cassidy A, Compston JE. Sex hormones and bone mineral density in elderly men. Bone Miner. 1993;20:133–40.

    Article  CAS  PubMed  Google Scholar 

  59. Szulc P, Delmas PD. Biochemical markers of bone turnover in men. Calcif Tissue Int. 2001;69:229–34.

    Article  CAS  PubMed  Google Scholar 

  60. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol. 1999;161:1219–22.

    Article  CAS  PubMed  Google Scholar 

  61. Daniell HW. Osteoporosis after orchiectomy for prostate cancer [see comments]. J Urol. 1997;157:439–44.

    Article  CAS  PubMed  Google Scholar 

  62. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000;163:181–6.

    Article  CAS  PubMed  Google Scholar 

  63. Higano C, Shields A, Wood N, Brown J, Tangen C. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology. 2004;64:1182–6.

    Article  PubMed  Google Scholar 

  64. Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 2002;87:3656–61.

    Article  CAS  PubMed  Google Scholar 

  65. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154–64.

    Article  CAS  PubMed  Google Scholar 

  66. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23:7897–903.

    Article  CAS  PubMed  Google Scholar 

  67. Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE, Paszat L. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol. 2010;184(3):918–23. https://doi.org/10.1016/j.juro.2010.04.068.

    Article  PubMed  Google Scholar 

  68. Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H, Resnick M. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol. 2001;166:1724–8.

    Article  CAS  PubMed  Google Scholar 

  69. Lenchik L, Kiebzak GM, Blunt BA. What is the role of serial bone mineral density measurements in patient management? J Clin Densitom. 2002;5(Suppl):S29–38.

    Article  PubMed  Google Scholar 

  70. Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med. 2008;358:1474–82.

    Article  CAS  PubMed  Google Scholar 

  71. Cummings SR, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet. 1993;341:72–5.

    Article  CAS  PubMed  Google Scholar 

  72. Tinetti ME. Clinical practice. Preventing falls in elderly persons. N Engl J Med. 2003;348:42–9.

    Article  PubMed  Google Scholar 

  73. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 2007;370:657–66.

    Article  CAS  PubMed  Google Scholar 

  74. Benton MJ, White A. Osteoporosis: recommendations for resistance exercise and supplementation with calcium and vitamin D to promote bone health. J Community Health Nurs. 2006;23:201–11.

    Article  PubMed  Google Scholar 

  75. Network NCC. Prostate cancer. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (2017). Accessed 21 Feb 2017.

  76. Smith MR, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345:948–55.

    Article  CAS  PubMed  Google Scholar 

  77. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169:2008–12.

    Article  CAS  PubMed  Google Scholar 

  78. Michaelson MD, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007;25:1038–42.

    Article  CAS  PubMed  Google Scholar 

  79. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med. 2007;146:416–24.

    Article  PubMed  Google Scholar 

  80. Bekker PJ, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19:1059–66. https://doi.org/10.1359/JBMR.040305.

    Article  PubMed  CAS  Google Scholar 

  81. Smith MR, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. de Bono JS, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005. https://doi.org/10.1056/NEJMoa1014618.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Ryan CJ, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–60. https://doi.org/10.1016/S1470-2045(14)71205-7.

    Article  PubMed  CAS  Google Scholar 

  84. Attard G, et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab. 2012;97:507–16. https://doi.org/10.1210/jc.2011-2189.

    Article  PubMed  CAS  Google Scholar 

  85. Ryan CJ, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48. https://doi.org/10.1056/NEJMoa1209096.

    Article  PubMed  CAS  Google Scholar 

  86. Agency EM. Summary of the European public assessment report (EPAR) for Zytiga. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002321/WC500112861.pdf. Accessed 20 Jan 2015.

  87. Tran C, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Beer TM, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33. https://doi.org/10.1056/NEJMoa1405095.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  89. Scher HI, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97. https://doi.org/10.1056/NEJMoa1207506.

    Article  PubMed  CAS  Google Scholar 

  90. Chowdhury S, et al. Fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide: data from randomised clinical trials. Ann Oncol. 2016;27:739P.

    Google Scholar 

  91. Agency EM. Summary of the European public assessment report (EPAR) for Xtandi. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002639/WC500144999.pdf. Accessed 20 Jan 2015.

  92. Choueiri TK, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373:1814–23. https://doi.org/10.1056/NEJMoa1510016.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  93. Choueiri TK, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17:917–27. https://doi.org/10.1016/S1470-2045(16)30107-3.

    Article  PubMed  CAS  Google Scholar 

  94. Escudier B, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–34. https://doi.org/10.1056/NEJMoa060655.

    Article  PubMed  CAS  Google Scholar 

  95. Escudier B, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27:3312–8. https://doi.org/10.1200/JCO.2008.19.5511.

    Article  PubMed  CAS  Google Scholar 

  96. Escudier B, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103–11. https://doi.org/10.1016/S0140-6736(07)61904-7.

    Article  PubMed  Google Scholar 

  97. Escudier B, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:1280–9. https://doi.org/10.1200/JCO.2008.19.3342.

    Article  PubMed  CAS  Google Scholar 

  98. Giannarini G, Petralia G, Thoeny HC. Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature. Eur Urol. 2011;61(2):326–40. https://doi.org/10.1016/j.eururo.2011.09.019.

    Article  PubMed  Google Scholar 

  99. Hudes G, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–81. https://doi.org/10.1056/NEJMoa066838.

    Article  PubMed  CAS  Google Scholar 

  100. Motzer RJ, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449–56. https://doi.org/10.1016/S0140-6736(08)61039-9.

    Article  PubMed  CAS  Google Scholar 

  101. Motzer RJ, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14:552–62. https://doi.org/10.1016/S1470-2045(13)70093-7.

    Article  PubMed  CAS  Google Scholar 

  102. Motzer RJ, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584–90. https://doi.org/10.1200/JCO.2008.20.1293.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  103. Motzer RJ, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24. https://doi.org/10.1056/NEJMoa065044.

    Article  PubMed  CAS  Google Scholar 

  104. Rini BI, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931–9. https://doi.org/10.1016/S0140-6736(11)61613-9.

    Article  PubMed  CAS  Google Scholar 

  105. Rini BI, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26:5422–8. https://doi.org/10.1200/JCO.2008.16.9847.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  106. Sternberg CN, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–8. https://doi.org/10.1200/JCO.2009.23.9764.

    Article  PubMed  CAS  Google Scholar 

  107. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688–96. https://doi.org/10.1200/JCO.1995.13.3.688.

    Article  PubMed  CAS  Google Scholar 

  108. Escudier B, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28:2144–50. https://doi.org/10.1200/JCO.2009.26.7849.

    Article  PubMed  CAS  Google Scholar 

  109. Eisen T, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst. 2012;104:93–113. https://doi.org/10.1093/jnci/djr511.

    Article  PubMed  CAS  Google Scholar 

  110. Lacouture ME, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008;13:1001–11. https://doi.org/10.1634/theoncologist.2008-0131.

    Article  PubMed  CAS  Google Scholar 

  111. Negrier S, Ravaud A. Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management. Eur J Cancer Suppl. 2007;5(7):12–9.

    Article  CAS  Google Scholar 

  112. Benson AB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22:2918–26. https://doi.org/10.1200/JCO.2004.04.132.

    Article  PubMed  CAS  Google Scholar 

  113. Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2007;4:CD000978. https://doi.org/10.1002/14651858.CD000978.pub3.

    Article  Google Scholar 

  114. Bjordal JM, Bensadoun RJ, Tuner J, Frigo L, Gjerde K, Lopes-Martins RA. A systematic review with meta-analysis of the effect of low-level laser therapy (LLLT) in cancer therapy-induced oral mucositis. Support Care Cancer. 2011;19:1069–77. https://doi.org/10.1007/s00520-011-1202-0.

    Article  PubMed  Google Scholar 

  115. Loprinzi CL, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst. 1990;82:1127–32.

    Article  CAS  PubMed  Google Scholar 

  116. Fearon KC, Barber MD, Moses AG, Ahmedzai SH, Taylor GS, Tisdale MJ, Murray GD. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol. 2006;24:3401–7. https://doi.org/10.1200/JCO.2005.04.5724.

    Article  PubMed  CAS  Google Scholar 

  117. Madeddu C, Maccio A, Panzone F, Tanca FM, Mantovani G. Medroxyprogesterone acetate in the management of cancer cachexia. Expert Opin Pharmacother. 2009;10:1359–66. https://doi.org/10.1517/14656560902960162.

    Article  PubMed  CAS  Google Scholar 

  118. Berk L, James J, Schwartz A, Hug E, Mahadevan A, Samuels M, Kachnic L. A randomized, double-blind, placebo-controlled trial of a beta-hydroxyl beta-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122). Support Care Cancer. 2008;16:1179–88. https://doi.org/10.1007/s00520-008-0403-7.

    Article  PubMed  Google Scholar 

  119. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 2009;10:559–68. https://doi.org/10.1016/S1470-2045(09)70112-3.

    Article  CAS  PubMed  Google Scholar 

  120. Network. NCC NCCN clinical practice guidelines in oncology: cancer-related fatigue. http://www.nccn.org/. Accessed 17 Feb 2010.

  121. Turner JS, Cheung EM, George J, Quinn DI. Pain management, supportive and palliative care in patients with renal cell carcinoma. BJU Int. 2007;99:1305–12. https://doi.org/10.1111/j.1464-410X.2007.06829.x.

    Article  PubMed  Google Scholar 

  122. Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schoffski P. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer. 2008;99:448–54. https://doi.org/10.1038/sj.bjc.6604497.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  123. Bamias A, Lainakis G, Manios E, Koroboki E, Gyftaki R, Zakopoulos N, Dimopoulos MA. Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib. J Chemother. 2009;21:347–50.

    Article  CAS  PubMed  Google Scholar 

  124. Bamias A, Lainakis G, Manios E, Koroboki E, Karadimou A, Zakopoulos N, Dimopoulos MA. Could rigorous diagnosis and management of hypertension reduce cardiac events in patients with renal cell carcinoma treated with tyrosine kinase inhibitors? J Clin Oncol. 2009;27:2567–9. https://doi.org/10.1200/JCO.2008.21.6028. author reply 2569–2570.

    Article  PubMed  Google Scholar 

  125. Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol. 2009;10:391–9. https://doi.org/10.1016/S1470-2045(09)70042-7.

    Article  PubMed  CAS  Google Scholar 

  126. Force T, Kerkela R. Cardiotoxicity of the new cancer therapeutics--mechanisms of, and approaches to, the problem. Drug Discov Today. 2008;13:778–84. https://doi.org/10.1016/j.drudis.2008.05.011.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  127. Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol. 2008;19:1613–8. https://doi.org/10.1093/annonc/mdn168.

    Article  PubMed  CAS  Google Scholar 

  128. Elice F, Rodeghiero F, Falanga A, Rickles FR. Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol. 2009;22:115–28. https://doi.org/10.1016/j.beha.2009.01.001.

    Article  PubMed  CAS  Google Scholar 

  129. Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol. 2009;27:4865–73. https://doi.org/10.1200/JCO.2009.22.3875.

    Article  PubMed  CAS  Google Scholar 

  130. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300:2277–85. https://doi.org/10.1001/jama.2008.656.

    Article  PubMed  CAS  Google Scholar 

  131. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133:381S–453S. https://doi.org/10.1378/chest.08-0656.

    Article  PubMed  CAS  Google Scholar 

  132. Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol. 2008;180:94–8. https://doi.org/10.1016/j.juro.2008.03.047.

    Article  PubMed  Google Scholar 

  133. European Medicines Agency. EU SmPC 06/01/2012 Nexavar -EMEA/H/C/000690 -IB/0031/G. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000690/WC500027704.pdf. Accessed 01 Jul 2017

  134. European Medicines Agency. EU SmPC 16/03/2012 Sutent -EMEA/H/C/000687 -IB/0034. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000687/WC500057737.pdf. Accessed 01 Jul 2017

  135. European Medicines Agency. EU SmPC 24/10/2011 Votrient -EMEA/H/C/001141 -II/0005, II/0006, II0008. http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001141/WC500094272.pdf. Accessed 01 Jul 2017

  136. European Medicines Agency. EU SmPC 06/02/2012 Avastin -EMEA/H/C/000582 -II/0048. http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf. Accessed 1 Jul 2017

  137. European Medicines Agency. Eu SmPC 02/09/2011 Torisel -EMEA/H/C/000799 -T/0039. http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000799/WC500039912.pdf. Accessed 01 Jul 2017

  138. European Medicines Agency. EU SmPC 22/11/2011 Afinitor -EMEA/H/C/001038 -II/0014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001038/WC500022814.pdf. Accessed 01 Jul 2017

Download references

Author information

Authors and Affiliations

  1. Service d’Urologie, Cliniques universitaires Saint Luc, Brussels, Belgium

    Bertrand F. Tombal, Christine Remacle & Monique Kasa Vubu

Authors
  1. Bertrand F. Tombal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christine Remacle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Monique Kasa Vubu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bertrand F. Tombal .

Editor information

Editors and Affiliations

  1. Department of Hematology-Oncology, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg

    Mario A. Dicato

  2. Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium

    Eric Van Cutsem

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tombal, B.F., Remacle, C., Vubu, M.K. (2018). Side Effects of Medical Cancer Therapy in Genitourinary Malignancies. In: Dicato, M., Van Cutsem, E. (eds) Side Effects of Medical Cancer Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-70253-7_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-70253-7_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-70252-0

  • Online ISBN: 978-3-319-70253-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation